Precision across the proteome
Move beyond the one-disease, one-target, one-drug paradigm by integrating polypharmacology, selectivity profiling, safety assessment and drug repurposing.
Guiding drugs toward beneficial on-targets and away from harmful off-targets.
IBIS Therapeutics describes its mission as accelerating drug discovery through an AI-driven Molecular Fingerprint™ Platform.
AI-driven insight
The platform evaluates interactions between diverse arrays of drug candidates and disease-modifying and toxicity-causing protein targets.
Actionable discovery
Turn large-scale molecular interaction data into information that can inform drug discovery and development decisions.